Edition:
United States

Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

36.82USD
26 Sep 2016
Change (% chg)

-- (--)
Prev Close
$36.82
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
524,258
52-wk High
$109.07
52-wk Low
$11.57

CLVS.OQ

Chart for CLVS.OQ

About

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth... (more)

Overall

Beta: 1.78
Market Cap(Mil.): $1,417.61
Shares Outstanding(Mil.): 38.50
Dividend: --
Yield (%): --

Financials

  CLVS.OQ Industry Sector
P/E (TTM): -- 42.52 36.60
EPS (TTM): -11.28 -- --
ROI: -86.55 -0.26 13.91
ROE: -275.77 -3.05 14.82

Clovis short sellers undaunted as stock price surges

NEW YORK Clovis Oncology Inc's share price has doubled in the past month, fueled by positive developments for the company's experimental cancer drug and takeover speculation. But some investors also appear to be increasing bets against the stock.

Sep 26 2016

Clovis short sellers undaunted as stock price surges

NEW YORK, Sept 26 Clovis Oncology Inc's share price has doubled in the past month, fueled by positive developments for the company's experimental cancer drug and takeover speculation. But some investors also appear to be increasing bets against the stock.

Sep 26 2016

BRIEF-Clovis Oncology -FDA has notified it is not currently planning to hold advisory committee meeting to discuss for Rucaparib

* FDA has notified co that FDA is not currently planning to hold advisory committee meeting to discuss NDA for Rucaparib Source text: [http://bit.ly/2c9EYtK] Further company coverage:

Sep 08 2016

BRIEF-Clovis enters into first amendment to license agreement between Clovis and pfizer

* Entered into first amendment to license agreement between Clovis and Pfizer, Inc.

Aug 30 2016

BRIEF-Clovis Oncology says FDA accepts co's new drug application for rucaparib for priority review

* FDA accepts Clovis Oncology's new drug application for rucaparib for priority review for the treatment of advanced mutant BRCA ovarian cancer

Aug 23 2016

BRIEF-Clovis Oncology Q2 adjusted loss per share $2.07 excluding items

* Clovis oncology announces q2 2016 operating results and corporate update

Aug 08 2016

UPDATE 2-Tesaro's ovarian cancer drug study succeeds, shares soar

* Shares of rival Clovis Oncology also rise (Adds details; analyst comments)

Jun 29 2016

BRIEF-Clovis Oncology Inc files for mixed shelf of up to $200 mln

* Clovis Oncology Inc files for mixed shelf of up to $200 million Source text: http://1.usa.gov/1XdI04i Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jun 10 2016

BRIEF-Clovis Oncology presents data from phase 2 studies of rucaparib

* Nineteen patients (9%) discontinued treatment because of an adverse event.

Jun 06 2016

BRIEF-Clovis Oncology reports Q1 loss per share $2.17

* Clovis oncology announces q1 2016 operating results and corporate update

May 05 2016

Competitors

  Price Chg
Eisai Co., Ltd (4523.T) ¥6,467 +45.00
Pfizer Inc. (PFE.N) $33.64 -0.62
AstraZeneca plc (AZN.L) 5,052.00p -47.00
BioMarin Pharmaceutical Inc. (BMRN.OQ) $95.87 --
TESARO Inc (TSRO.OQ) $107.82 --
AbbVie Inc (ABBV.N) $64.07 -0.91
Novartis AG (NOVN.S) CHF77.65 -0.35
Johnson & Johnson (JNJ.N) $117.78 -1.03
Eli Lilly and Co (LLY.N) $79.52 -1.64
GlaxoSmithKline plc (GSK.L) 1,641.50p +8.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.